Ironwood Pharmaceuticals (NASDAQ:IRWD) Insider Sells $578,062.80 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 127,890 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the completion of the sale, the insider owned 313,680 shares of the company’s stock, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ironwood Pharmaceuticals Price Performance

IRWD stock traded down $0.20 on Friday, hitting $4.47. 2,773,273 shares of the company were exchanged, compared to its average volume of 2,588,706. The stock has a market capitalization of $728.88 million, a price-to-earnings ratio of 7.45 and a beta of 0.20. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.67 and a twelve month high of $5.78. The business’s fifty day moving average is $3.88 and its two-hundred day moving average is $3.95.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $106.51 million during the quarter, compared to analyst estimates of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. Equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC boosted its holdings in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the last quarter. LSV Asset Management bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth $30,000. Captrust Financial Advisors bought a new stake in shares of Ironwood Pharmaceuticals in the second quarter worth $32,000. Jump Financial LLC acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at $34,000. Finally, DGS Capital Management LLC acquired a new position in Ironwood Pharmaceuticals in the fourth quarter worth about $35,000.

Wall Street Analysts Forecast Growth

IRWD has been the subject of several research analyst reports. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Finally, Zacks Research raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 1st. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.